Ambrisentan — Discount Pricing

Other medications in Heart & Cardiovascular

• Amlodipine
• Apixaban
• Atenolol
• Atorvastatin
• Azilsartan
• Bempedoic Acid
• Benazepril
• Bisoprolol

About Ambrisentan

Ambrisentan is a vital medication used to treat Pulmonary Arterial Hypertension (PAH), a serious condition affecting the heart and lungs. For those living with PAH, managing prescription costs can be a significant challenge. TheDrugClub is dedicated to helping members access affordable pricing on crucial medications like ambrisentan, ensuring you can focus on your health without undue financial burden.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ambrisentan is approved for (FDA label)

Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Ambrisentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ambrisentan (FDA label)

WARNING: EMBRYO-FETAL TOXICITY Ambrisentan tablets are contraindicat ed for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals [see Contraindications (4.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.1)]. Therefore, for females of reproductive potential, exclude pregnancy before the initiation of treatment must use acceptable methods of contraception during treatment with ambrisentan tablets. Advise use of effective contraception before initiation, during treatment, and for one month after treatment with ambrisentan tablets [see Dosage and Administration (2.2), Contraindications (4.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)]. When pregnancy is detected, discontinue ambrisentan tablets as soon as possible (5.1). WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Based on animal data ambrisentan tablets may cause fetal harm if used during pregnancy (4.1, 5.1, 8.1). Females of reproductive potential: Exclude pregnancy before the start of treatment. Use effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with ambrisentan tablets. (2.2, 4.1, 5.1, 8.1, 8.3) W hen pregnancy is detected, discontinue ambrisentan tablets as soon as possible (5.1).

Source: FDA prescribing information (DailyMed). Set ID: 291a782a-77e1-8a8e-e1c8-2626f305c2b7. SPL document ID: 2950aca0-011d-ea24-bbd4-4557a0fe1aec. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ambrisentan (FDA label)

5 mg and 10 mg film - coated tablets for oral administration Each 5 mg tablet is pale pink, biconvex, beveled edged, arc square film-coated tablet. Engraved "APO" on one side, "A5" on the other side. Each 10 mg tablet is deep pink, biconvex, oval film-coated tablet. Engraved "APO" on one side, "A10" on the other side. Tablet: 5 mg and 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 291a782a-77e1-8a8e-e1c8-2626f305c2b7. SPL document ID: 2950aca0-011d-ea24-bbd4-4557a0fe1aec. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ambrisentan (FDA label)

Clinically significant adverse reactions that appear in other sections of the labeling include: Embryo-fetal Toxicity [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ] Fluid Retention [see Warnings and Precautions (5.2) ] Pulmonary Edema with PVOD [see Warnings and Precautions (5.3) ] Decreased Sperm Count [see Warnings and Precautions (5.4) ] Hematologic Changes [see Warnings and Precautions (5.5) ] Most common adverse reactions (>3% compared to placebo) are peripheral edema, nasal congestion, sinusitis, and flushing ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 291a782a-77e1-8a8e-e1c8-2626f305c2b7. SPL document ID: 2950aca0-011d-ea24-bbd4-4557a0fe1aec. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ambrisentan (FDA label)

Pregnancy ( 4.1 ) Idiopathic Pulmonary Fibrosis ( 4.2 ) 4.1 Pregnancy Ambrisentan tablets may cause fetal harm when administered to a pregnant female. Ambrisentan tablets are contraindicated in females who are pregnant. Ambrisentan was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Use in Specific Populations (8.1)]. 4.2 Idiopathic Pulmonary Fibrosis Ambrisentan tablets are contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF), including IPF patients with pulmonary hypertension (WHO Group 3) [see Clinical Studies (14.4) ].

Source: FDA prescribing information (DailyMed). Set ID: 291a782a-77e1-8a8e-e1c8-2626f305c2b7. SPL document ID: 2950aca0-011d-ea24-bbd4-4557a0fe1aec. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ambrisentan (FDA label)

Fluid retention may require intervention ( 5.2 ). If patients develop acute pulmonary edema during initiation of therapy with ambrisentan tablets, consider underlying pulmonary veno-occlusive disease and discontinue treatment if necessary ( 5.3 ). Decreases in sperm count have been observed in patients taking endothelin receptor antagonists ( 5.4 ). Decreases in hemoglobin have been observed within the first few weeks; measure hemoglobin at initiation, at 1 month, and periodically thereafter ( 5.5 ). 5.1 Embryo-fetal Toxicity Based on data from animal reproduction studies, ambrisentan tablets may cause fetal harm when administered during pregnancy and is contraindicated during pregnancy. The available human data for endothelin receptor antagonists do not establish the presence or absence of major birth defects related to the use of ambrisentan tablets. Advise patients who can become pregnant of the potential risk to a fetus. Obtain a pregnancy test prior to initiation of treatment with ambrisentan tablets.

Source: FDA prescribing information (DailyMed). Set ID: 291a782a-77e1-8a8e-e1c8-2626f305c2b7. SPL document ID: 2950aca0-011d-ea24-bbd4-4557a0fe1aec. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.